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509 - Viruses as the cause of cancer
IMoS361 Epidemiology of genital Human Papillomavirus
infection and risk for development of cancer
Joakim Dillner
The Microbiology & Tumor Biology Center, Karolinska Institute, Stockholm,
Sweden
Infection with the oncogenic types of Human Papillomavirus (HPV),
particularly type 16, is established as the major cause ofcervical intraepithe-
lial nroplasia (CIN) and invasive cervical cancer. In recent years, several
prospective studies have also implicated HPV 16 infection as a major cause of
vulvar, vaginal, anal, penile, fmgertip and tonsillar cancers.
The vast majority of infections arc transient and become undetectable
within t - 2 years. A persistent infection with continued active expression of
the viral transforming proteins is considered a necessary step in the
pathogenesis of cervical cancer.
The major mode of transmission is sexual: Infection with oncogenic HPV
types can not be demonstrated in virginal women, neither by serology nor
by HPV DNA detection. About t % of children in presexually active ages
are seropositive.
The seroprevalence ofthe infection shows a rapid increase in the ages after
coitarche. In Sweden, the HPV 16 seroprevalence is linearly dependent on
the lifetime number of sexual partners, increasing with about 4%/sexual
parmer. Seropositivity is stable over time also after viral clearance and
correlates with cumulative life-time HPV exposure.
HPV seroprevalence correlates with seroprevalence of other STDs, such
as Chlamydia or HSV-2, and there has been a concomitant increase ofHPV
seroprevalence and seroprevalence ofother STDs between the I%O:ies to the
1980:ies in the Nordic countries.
A cervical HPV DNA-positive woman has a > tOO-fold excess risk to
have an existent cervical neoplasia and a t6-fold excess risk to develop
invasive cervical cancer in the future.
Possible preventive actions that are presently being evaluated include
organized screening for HPV infection and prophylactic HPV vaccination.
IMoS3S1 Hepatitis Band Cviruses and cancer
Ma C. Kew
University of the Witwatersralld, Johannesburg, South Africa
Of the currently recognised hepatotropic viruses, only hepatitis Band C
viruses are known to cause hepatocellular cancer in humans. Hepatocarci-
nogenesis is a C'o.mplex stcpmsc proc~!; that evolves over several or many
years and precisely how hepatitis viruses contribute to this process is
uncertain. There is, however, mounting evidence that both direct and
indirect carcinogenic mechanisms are involved with both viruses. Chronic
necroinflammatory disease, in the form of cirrhosis or occasionally chronic
hepatitis, induced by both hepatitis Band C viruses, acts as a tumour
promoter by markedly increasing the hepatocyte turnover rate, modifying
normal cell-to-cell and cell-to-extracellular matrix interactions, impairing
DNA repair processes, and generating mutagenic oxygen reactive species.
Hepatitis B virus is a DNA virus that is integrated into cellular DNA in the
great majority of hepatitis B virus-related hepatocellular carcinomas, and
there is increasing evidence that its direct oncogenic effect is mediated by the
X protein that is expressed from integrated viral DNA. This protein
transactivates a number of cellular genes and may thus influence cellular
proliferation and differentiation or apoptosis. It also compromises DNA
repair and may allow the accumulation of potentially transforming muta-
tions. Insertional mutagenesis In cis may playa pathogenetic role in a small
percentage of tumours. In contrast, hepatitis C virus is an RNA virus that
does not integrate into cellular DNA and there is less evidence that it is
directly oncogenic. There is, however, emerging evidence that the core
protein and NS3 protein may exert a transforming effect from an extra-
chromosomal position. Hepatitis Band C viruses interact synergistically in
the pathogenesis of hepatocellular carcinoma.
510 - New diagnostics and therapeutic approaches ...
IMoS391 Definitions of invasive fungal infections
Sibel Ascioglu
Hacettepe University, Dept. of Infectious Diseases, Ankara, Turkey
Clinical research addressing the epidemiology, diagnosis and treatment of
invasive fungal infections (IFl) is accumulating in the medical literature.
Unfortunately, differences in definitions, nomenclature, and diagnostic
criteria complicate comparison ofresults and collaboration between centers.
Therefore EORTC/IFICG launched a project to reach a consensus on
definitions of IF! in cancer patients. The purpose of this effort was to
improve the ability to compare protocols, therapeutic interventions and
eliminate confusion in communication for both clinicians and researchers by
standardizing the definitions. This project has been designed and proceeded
in three steps: (1) Defining the problem. (2) Assessing the current preferences
among investigators in defming and classifying IF!. (3) Composing a new
proposal for definitions ofIF!.
A task force was created in t997 to systematically review the literature,
describe problems related to heterogeneity ofstudy populations, and abstract
previously used definitions of IF!. The task force was composed of 12
members of IFICG and later with the invited members of NIAID/MSG
formed a consensus committee. As a result ofjoint efforts of the committee
members, a new clas..ification based on the level ofcertainty for the diagnosis
ofIFI was devised. This proposal includes both diagnostic criteria for proven
IFl and also classification criteria for probable and possible diseases. Three
elements formed the basis of these definitions: host factors, clinical features
and microbiological results. We have chosen a format that is easy and flexible
to apply to individual patients in daily clinical practice.
IMoS40 I Diagnostic options for early detection of invasive
aspergillosis
P. E. Verweij
Departmmt ofMedical Microbiology, University Medical Cmter 8t Radboud,
Nijmegm, Netherlands
The early diagnosis ofinvasive aspergillosis (IA) is very important in order to
start antifungal treatment promptly. Since the yield of conventional diag-
nostic tests is low, most patients who are suspected for invasive fungal
infection are treated empirically. This approach may allow early treatment
of patients with IA but also results in unnecessary treatment ofa significant
proportion of patients with infection. These patients are exposed to drug-
related toxicity especially if amphotericin B desoxycholate is used for
primary therapy. A management strategy that allows a better selection of
patients that require antifungal therapy is desirable. Improved selection of
patients that require antifungal therapy can be achieved if they are system-
atically screened during the period ofhigh risk for the presence ofa marker
that is indicative of IA. Patients' blood can be screened regularly for the
presence ofcirculating Aspergillus antigen or DNA. Once antigen or DNA is
detected additional diagnostic procedures such a. high resolution CT ><:an
can be used to confirm the presence of infection. Patients with confirmed
disease can be treated pre-emptively. The assays that are used to screen
patients have to be both sensitive and specific, and both antigen detection and
PCR appear to perform well in this respect. However, several issues need to
be resolved before prospective screening of patients can be implemented.
Furthermore, the performance of antigen or DNA detection has been
evaluated almost exclusively in patients with hematological malignancies,
but other patient groups at risk remain to be investigated.
IMoS411 Surveillance of nosocomial fungal infections
Patricia Munoz
Hospital General Universitario "Gregorio Maranon", Madrid, Spain
Nosocomial fungal infections caused by Candida, Aspergillus or new multi-
resistant pathogens are on the rise. They still cause a very high morbidity and
mortality proving that our therapeutic and prophylactic measures lack
efficacy. Epidemiological surveillance for nosocomial micoses is highly
recommended and should include the periodic review of hopital's micro-
biologic, histopathologic and postmortem data. A very high index of
suspicion for prompt diagnosis in high-risk patients is also desirable.
Previous colonization is a recognized risk factor for developing invasive
candidiasis or aspergillosis, although the positive and negative predictive
values of these cultures are different for each group of patients at risk.
Molecular-biology methodology may detect the presence of fungus more
accurately than culture and serological methods. They may also be helpful in
the analysis of outbreaks and nosocomial transmission. However, the cost-
effectivenes of microbiological surveillance out of an outbreak situation
remains an unresolved issue. Environmental culturing for Aspe"lillu$
organisms may be useful to detect failures in air-quality conrrol measures
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and is recommendcd when cascs ofAspergillus infection are detected but they
are not recommended on routine basis. Surveillance cultures of high risk
patients, in search ofAspergillus or Candida. may guide thc administration of
preemptive or prophylactic antifungals, However, the real efficacy of this
surveillance practices, remains to be defined.
511 - Is malareia being rolled back
ITuS31 Malaria vaccine development Approaches and status
J. Cohen
SmithKlitle Beecham Biologicals, Rixensart. Belgium
Malaria remains onc ofthc world most deadly diseases. The World Health
Organization estimates that there are 300 to 500 million clinical cases of
malaria annually, causing 1.1 to 1.7 million deaths. The vast majority of
deaths occurs among children under 5 years ofage and 90% ofmalaria cases
are in sub-Saharan Africa.
While various control mcasures can contribute to amelioratc this situa-
tion, it is generally accepted that. in the long run, vaccines are likely to be the
most effective and cost efficient way to fight this disease. Fortunately, there
exist today convincing preclinical and preliminary clinical data suggesting
that the development of a malaria vaccine is needed feasible.
In the first part of this presentation, we will describe the various
approaches rescarchers in this field have employed in their attempts to
develop vaccines targeting the different stages of the Plasmodium falciparum
parasite life cycle. The rationale and results obtained with each approach will
be described.
We will then focus on one promising malaria vaccine candidate, desig-
nated R TS, S/SBAS2, that has been developed by SmithKline Beecham
Biologicals and its collaborators. This vaccine has recently yielded unprece-
dented efficacy results in clinical trials conducted both under laboratory and
natural (field) challenge conditions. Avenues for further development and
improvement of this vaccine will be described.
!TuS41 Transmission blocking drugs or vacdnes for control of
malaria
R. Sauerwein
University Medical Centre St Radboud, Dept ofMedical Microbiology,
Nijmegftl, Netherlands
The rate of malaria transmission is an important denominator in the
epidemiology of clinical of malaria. Malaria parasit.... arc distributed in the
population by Plasmodium-infected Anopheles mosquitoes; the number of
infected mosquitoes can vary significantly per geographical area. The more
intense the transmission, the younger the age at which malaria immunity and
protection from lethal diseasc is acquired. Infectiousness ofthe human host to
mosquitoes is determin..-d by the presence of sexual stages (gametocytes
[gct]) in the circulation. Transmission-blocking (TB)-vaccines or drugs aim
at a reduction of the human infectious reservoir by killing or inactivating
gct's and form an important component in malaria control. TB vaccines and
drugs can directly reduce morbidity and mortality but also may act as an
adjunct to other malaria vaccines by reducing the spread ofresistant strains.
TB-immunity induced by vaccines is antibody-mediated and a number of
target molecules on the parasite membrane have been identified. Some
recombinant proteins are in the process of production for clinical testing.
TB-drugs include artemisinin, primaquine and its derivative tafenoquine.
These drugs are primarily used for treatment or prophylaxis, but also show
potent killing effects on gct's. The effect oftransmission reductions or clinical
malaria will depend on the rate of transmission and is strongly geographi-
cally determined.
512 - Pharmacodynamics of antifungals
ITussl Development of resistance dUring antifungal therapy
D. Milatovic
Eijkman- Winkler ItlStitute. University of Utrecht, Netherlatlds
In the last decade emergence of resistance during antifungal treatment has
become a well recognized problem in HIV-infected patients receiving long
term prophylaxis and treatment with fluconazole for oropharyngcal candi-
diasis. Molecular typing revealed that in most cases development of
resist:mce of the original C. albicans strain is encountercd. but coexistencc
ofdifferent subpopulations exhibiting various degrees of resist:mce have also
been demonstrated. Risk factors identified for the development offlucona-
zole resistance were low CD4 + counts, previous exposure to the drug and a
total cumulative dose of at least 10 g. No difference in the occurrence of
resistancc could be observed in patients receiving continuous versus inter-
mittent therapy. In non-AIDS patients emergence of azole resistant C.
albicans has been rarely reported. However, an increased incidence of
infections due to Candida spp. intrinsically resistant to fluconazole such as
C. glabrata and C. krusei has been observed in neutropenic patients as well as
in intensive care patients receiving azole drugs for prophylaxis or treatment.
In the last years progress has been made in elucidating the molecular
mechanisms contributing to resistance development of Candida to the
azoles which include enhanced expression of multidrug efllux pumps,
target enzyme overexpression and point mutation of its encoding gene
resulting in decreased affinity to the drug. Recurrences of cryptococcal
meningitis in AIDS patients during maintenance therapy with azoles have
infrequently been associated with the emergcnce of azoic-resistant strains.
Although there are case reports ofinfections due to amphotericin B resistant
yeasts, development of resistance to this antifungal agent appears to bc
uncommon. Flucytosin resistance is known to develop frequently during
monotherapy and is therefore uscd only in combination.
ITuS6! Pharmacodynamics of antifungals
D. Andes
University of Wiscotlsill. Madisotl. United States
PK/PD investigations of antibacterials have been used to predict outcomes
against both susceptible and resistent pathogens. For example, studies with
b-lactama have demonstrated that when dosing achieves drug levels exceed-
ing aT> MIC of at least 40% efficacy is observed against bath susceptible
and resistant pathogens. These observations have been important in the
development appropriate dosing strategies and susceptibility breakpoints.
Similar study with antifungal drugs has been limited. Recent studies have
begun to address several important PKfPD questions. Investigation ofthe in-
vivo time course activity ofcurrently available antifungal classes have found
that some demonstrate concentration dependent killing while others do not.
In addition, some antifungal compounds have demonstrated prolonged
persistent effects or postantifungal effects (PAFE) while others have not.
Studies have also demonstrated that different PK/PD parameters predict in-
vivo outcomes for these drugs. Fluconazole demonstrated no in-vivo
concentration dependent killing against susceptible or resistant C. albicans
and in-vivo exposures did, however, result in significant PAFEs. The ratio of
the 24 hr AUC/MIC was the PK/pDP that we, a moat closely associated
with outcomes. Furthermore, similar efficacy was observed against both
susceptible and resistant C. albicans when the magnitude of the 24 hr AUC/
MIC exceeded a value of 25. Similarly, study with f1ucytosine did not
demonstrate concentration dependent killing. Flucytosine therapy did not,
however, result in prolonged PAFEs. T > MIC was the PK/PDP predictive
of efficacy. Amphotericin B demonstrated both concentration dependent
killing and prolonged PAFEs. Peak level/MIC was the parameter best
prcdictive of in-vivo outcomes against Candida species.
These initial studies suggest that further PK/PD analysis of current and
developmental antifungals can offer important dosing Information for initial
clinical trials, effective treatment ofresistant pathogens and the development
of susceptibility breakpoints.
ITuS71synergism between antifungals
J. W. Mouton
Callisius Wilhe/mitla Hospital, Nijmegell, Netherlands
Infections caused by fungi are difficult to treat and arc increasing. Only a few
antimycotic agents are available and partly because of the diversity of fungi,
most species are susceptible to only a few ofthem. Combination therapy is an
alternative. The value and/or efficacy of combination therapy can be
evaluated in vitro, in vivo models and in human trials. Most studies have
been done in vitro by checkerboard type experiments. However, the
interpretation is difficult. Recently, models have become available to fit to
these type of data, such as the Greco model of interaction and the Uli>s
model. The results of these models can be used in simulations to determine
possible effects in vivo. In order to use these models, data have to be of a
quantitative nature. Methods to obtain quantitative readings such as extinc-
rion as a measure of antimycotic effect ming specific dyes are now available
for filamentous fungi. For instance. in vitro synergy has thus been shown for
